$0.00
$1.00
bear $0.00
base $0.00
bull $1.00
margin of safety $0.10
market price* $34.56
Business condition attached to the margin of safety
The company shows positive owner earnings (operating cash flow after stock compensation, before working-capital swings) for at least three consecutive quarters.
UroGen Pharma sells two drugs built on the same gel technology: Jelmyto and Zusduri, which are mitomycin formulations delivered in a gel to ablate tumors. Zusduri launched late in the second quarter of 2025. Revenue rose from $90.4 million in 2024 to $109.8 million in 2025, and to $123.4 million in just the first half of 2026 (about $72.5 million in the second quarter alone, against $24.2 million a year earlier). Gross margin is very high, about 89% in 2025. The problem is what the business costs to run. Selling, research and administrative spending was $222.2 million in 2025, and in every year we measured (2018 through 2025) the company had negative owner earnings, which we define as cash from operations, minus the swing in receivables, inventory and payables, minus stock-based pay, minus the capital spending needed to stay in business. By that measure it lost about $3.35 per share in 2018, $4.91 in 2019, $5.49 in 2020, $4.40 in 2021, $4.10 in 2022, $3.00 in 2023, $2.66 in 2024 and $3.09 in 2025 (per-share figures for 2018 to 2020 use the share count shown on each annual report's cover). In 2025, reported operating cash flow was also depressed by about $26 million as receivables, inventory and prepaid costs (net of payables) built up during the Zusduri launch; our figures remove that timing effect. In the first half of 2026, the same measure was still negative, roughly $35 million. Net losses did narrow from $23.6 million in the first quarter to $14.4 million in the second. We could not fully reconcile 2025 operating cash flow to the net loss from the line items we examined; a gap remained that we could not attribute to a specific item. Our approach credits only what is contracted, proven or already under way. Rising sales of Zusduri are real, but we do not yet have evidence that costs will stay flat while sales grow, so no future profit is credited in the base case. Financing matters. At June 30, 2026 the company held about $108 million in cash and marketable securities and owed $200 million to lender Pharmakon at a fixed 8.25%, repayable in four equal quarterly payments starting in the first quarter of 2030. A further $50 million can be drawn until June 30, 2027. Separately, the company owes RTW Investments tiered payments based on worldwide net sales of Jelmyto and Zusduri, and RTW holds a security interest in those products. Management states that current cash is sufficient to fund operations beyond one year, but also says it may need more capital if sales fall short, and the company sold shares in 2025 (about 416,000 shares) and 2024 (about 3.4 million shares). Share count rose from about 22.8 million in 2022 to about 50.4 million in the second quarter of 2026, so shareholders have been diluted. Bear case, $0.00 per share: revenue stops growing at roughly the current level, spending stays near current levels, and owner earnings remain negative at about the first-half 2026 pace, around $70 million a year. Cash plus the extra $50 million loan tranche would last roughly two years, and the $200 million loan comes due starting in 2030. In that path shareholders are left with nothing. We record zero rather than a negative figure because shareholders cannot be asked to pay in more than they own. Base case, $0.00 per share: the second-quarter 2026 run rate, roughly $290 million of annual revenue, is real, but at recent cost levels the company is still losing money on our measure, and we cannot name a signed contract or a proven pattern that closes the gap. Zusduri's patents are expected to expire in 2031, which also limits how long any profit would last. With no evidenced source of positive owner earnings, we assign no value. Bull case, $1.00 per share: sales keep growing at a pace like the first half of 2026 while spending is held near current levels, so owner earnings turn modestly positive, on the order of $10 million a year, and last until the 2031 Zusduri patent expiry. That is worth roughly $1 per share at a 6% discount rate. We did not credit new products under study, such as UGN-103 and UGN-104, because they are not yet approved. What would prove this wrong: several consecutive quarters of positive owner earnings, or evidence that spending falls while sales hold. Either would move the base case up materially. Because the base case is zero and the upside is small relative to the risk of dilution or lender pressure, the margin-of-safety price is small, and it applies only once profitability is demonstrated.